Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12390139 | 0.89 | STK17B (0.54) | NPSR1STK17BSTK17AADORA2AADORA1 | |
| SCHEMBL8889354 | 0.83 | SIRT5 (0.60) | NPSR1BRD4SIRT5BCHEMEN1 | |
| SCHEMBL31436060 | 0.82 | STK17B (0.58) | NPSR1STK17BSTK17AADORA2AADORA1 | |
| SCHEMBL12390142 | 0.81 | TDP1 (0.49) | STK17BSTK17AADORA2AADORA1ADORA2B | |
| SCHEMBL12390151 | 0.81 | TDP1 (0.49) | STK17BSTK17AADORA2AADORA1ADORA2B | |
| SCHEMBL6559442 | 0.78 | ATM (0.55) | NPSR1CYP3A4IDO1CA1CA12 | |
| SCHEMBL16134193 | 0.77 | STK17B (0.51) | STK17BSTK17AADORA2AADORA1ADORA2B | |
| SCHEMBL31436080 | 0.77 | TDP1 (0.58) | STK17BSTK17AADORA2AADORA1ADORA2B | |
| SCHEMBL31436112 | 0.77 | TDP1 (0.62) | STK17BSTK17AADORA2AADORA1ADORA2B | |
| SCHEMBL31436097 | 0.76 | STK17B (0.50) | STK17BSTK17AADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999101-B2 | Genetic material complexing and internalizing capacity; low cytotoxicity; such as 2-[4-(3-amino-propylamino)-6-tetradecylamino-[1,3,5]triazin-2-ylamino]-ethanethiol or its disulphide dimer | POLITECNICO DI MILANO (IT) | 2011-08-16 | — | — | US | disclosed |
| US-7999101-B2 | Genetic material complexing and internalizing capacity; low cytotoxicity; such as 2-[4-(3-amino-propylamino)-6-tetradecylamino-[1,3,5]triazin-2-ylamino]-ethanethiol or its disulphide dimer | POLITECNICO DI MILANO (IT) | 2011-08-16 | — | — | US | disclosed |
| US-20080146518-A1 | Cationic Lipids for the Transfection of Nucleic Acids | POLITECNICO DI MILANO (IL) | 2008-06-19 | — | — | US | disclosed |
| US-20080146518-A1 | Cationic Lipids for the Transfection of Nucleic Acids | POLITECNICO DI MILANO (IL) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146518-A1 | Cationic Lipids for the Transfection of Nucleic Acids | AARS1, HARS1, LPAR3 | NPSR1 1716/4885STK17B 4300/4885STK17A 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.